布地奈德混悬液联合硫酸特布他林雾化吸入治疗AECOPD30例临床观察

目的研究布地奈德混悬液联合硫酸特布他林雾化吸入对慢性阻塞性肺病急性加重期（AECOPD）的临床疗效。方法对60例AECOPD住院患者随机分为观察组与对照组。观察组30例,在常规治疗的基础上给予布地奈德混悬液2mg和硫酸特布他林雾化液5mg加生理盐水2ml联合雾化吸入治疗,2次/d;对照组30例,在常规治疗的基础上给予给以硫酸特布他林雾化液5mg加生理盐水2ml治疗,2次/d,对两组患者用药7d后的临床症状、血气分析及第一秒用力呼气容积占预计值百分比（FEV1%预计值）变化情况进行比较分析。结果两组治疗前后PaO2、PaCO2、FEV1%预计值比较,差异有统计学意义（P〈0.05）,两组间各对应指标相比较,差异均有统计学意义（P〈0.05）。两组的年龄、性别、发病、病程等构成情况大致相同。结论布地奈德联合硫酸特布他林雾化吸入对AECOPD能迅速缓解病情,畅通呼吸道,改善肺功能,疗效优于单一用药,是治疗AECOPD的有效选择。

Budesonide combined inhalation of terbutaline treatment AECOPD 30 Cases

Objective Budesonide combined inhalation of terbutaline in chronic obstructive pulmonary disease （ AECOPD） in clinical efficacy. Methods 60 patients with AECOPD inpatients were randomly divided into two groups and the control group. 30 cases observed in the routine treatment given Budesonide 2 mg and terbutaline aerosol saline solution plus 2 ml 5 mg combined inhalation therapy,2 times / day; the control group of 30 patients,on the basis of routine treatment given to give terbutaline atomization treatment 5 mg plus 2 ml normal saline,2 times / day,7 days after the two groups of patients the clinical symptoms of drug use,blood gas analysis and the first second percentage of total estimated value of expiratory volume （ FEV1% predicted value） changes were compared. Results Both before and after treatment PaO2,PaCO2,FEV1% predicted value,the difference was statistically significant （ P 0. 05） ,between the two groups compared with the corresponding indicators,the differences were statistically significant （ P 0. 05）. Two groups in age,gender,onset,duration and other similar composition. Conclusion budesonide inhalation of terbutaline on AECOPD rapid remission of disease,respiratory flow,improve lung function,more effective than single agent,is the treatment of AECOPD are effective choice.